A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
about
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsMantle cell lymphoma: observation to transplantationThe Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3KIdelalisib in the management of lymphoma.Drug monographs: belinostat and idelalisib.Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δIdelalisib: first global approval.The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Idelalisib for the treatment of non-Hodgkin lymphoma.Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.Current regimens and novel agents for mantle cell lymphoma.Phosphoinositide 3-kinase inhibitors in lymphoma.MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?Rethinking clinical response and outcome assessment in a biologic age.Novel agents in mantle cell lymphoma.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Prognosis and outcome of stem cell transplantation for mantle cell lymphoma.Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.Treatment options for mantle cell lymphoma.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Will new drugs change the standard of care for patients with mantle cell lymphoma?
P2860
Q26772907-44A4AA9A-7478-48BF-8E46-2E9E7ADB7CC5Q26782270-9F63D859-F3C2-4DCC-A19C-4E2F7EB40F3EQ26851417-5D489055-E08C-4DFD-9B1B-032C18BC226CQ27025812-A19611F2-854D-4215-95B9-26465F7623CAQ27687567-D382A3D5-C69A-4CFB-BA43-FD871DFB431BQ28075606-945469D8-EA43-455F-B267-8B0AFDFB165CQ28256317-FAD66A60-FCB7-44AC-8DD9-D672146B8E83Q31070331-609691D4-55D2-4395-A6AE-83D6F61337EDQ33421147-8AD71045-C521-4047-9397-EA89D545A2F8Q33433009-5F15BCB1-B6C2-49DF-BD1A-73C6D82C3BF8Q34452767-ED868237-1DA0-402E-819F-0D8FD8953758Q34529311-6556398A-31BD-4A62-864F-085197DBF736Q35057942-40470C7B-31F3-45AE-8BEA-71D1DEB05379Q35221596-CAA998FC-B3DC-485F-91C7-010DE526B38BQ35237924-81B5316F-41FB-4D40-93F7-26A55E280FD2Q35859219-F2DD66EF-8D5C-4FBE-8901-EC6A152F430CQ36000944-02B10974-DA5E-4245-ABAA-8DB6F612BA85Q36436997-14011806-6A2A-4D33-82A3-A3D3C108CC1EQ36685569-681F41FA-67BA-46CB-9A0B-1B7FD0BAB60DQ37079141-E29D286E-5DA1-4702-9E58-BF59270734D3Q37114445-7BE5A8F2-27C7-4064-8572-38BAFF85F093Q37613320-1F4D8CB6-4EAC-433D-9A76-154FF5962B7AQ37636965-50232ED5-C108-4A56-80FC-515978852193Q37706550-BD6D8357-D2C9-4688-BC04-029DE1BC30B8Q38224186-760DA7EE-144D-46C5-8C7A-57DAAF2A9AF4Q38229531-0532BDC7-5DB5-436D-8425-576085F80F7BQ38233772-D53095CD-019D-4EA1-8AF6-82AD821388CCQ38237619-9A7ED8C4-55EE-4F1E-A4D0-6CA6767C3E61Q38263806-E3F5F69C-7AA5-40CC-86CA-CA42947776E2Q38364936-A6A35DAC-FD5E-4BA6-97A4-69E7096C3063Q38373698-B54A6B91-1BC6-41B4-B5F6-EEDF3A4407EDQ38382492-1911162D-8BE8-47D1-B84F-FF14D9C1C9BEQ38480777-33EE9041-31E4-48AC-8331-8DD86E29D76BQ38516704-271499DC-24B0-4A33-BCC8-BB0F6303E39DQ38521775-00F637E0-C536-4222-A4C3-B6F9DDD40C92Q38532268-1318F8D4-4AB7-438B-9ADC-F756A4DA85C8Q38535489-B9BBB6C9-D3A7-4238-AC79-418FF4AABAB9Q38584922-B6F7BC59-4E44-4934-86C5-AC3BA964716CQ38594364-28DC5D49-73F8-4656-BBD8-DEC41EBD2855Q38658549-6B6E01A3-55AD-4EE2-87B0-A732D3D302DD
P2860
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@ast
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@en
A phase 1 study of the PI3Kδ i ...... efractory mantle cell lymphoma
@nl
type
label
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@ast
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@en
A phase 1 study of the PI3Kδ i ...... efractory mantle cell lymphoma
@nl
prefLabel
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@ast
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@en
A phase 1 study of the PI3Kδ i ...... efractory mantle cell lymphoma
@nl
P2093
P2860
P1433
P1476
A phase 1 study of the PI3Kδ i ...... ry mantle cell lymphoma (MCL).
@en
P2093
Brad S Kahl
Don M Benson
Ian W Flinn
Jennifer R Brown
Nina D Wagner-Johnston
Richard R Furman
Sissy Peterman
Stephen E Spurgeon
Steven E Coutre
P2860
P304
P356
10.1182/BLOOD-2013-11-537555
P407
P50
P577
2014-03-10T00:00:00Z